Oramed Pharmaceuticals Inc. (ORMP): R&D Expense
$6.38M
Year ended 2025-12-31
$4.74M
Trailing 12 months to 2026-06-30
-38.7%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.38M | +0.9% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $6.32M | -29.5% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $8.97M | -67.5% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $27.64M | n/a | 2024-03-06, From 2022-01-01 |
| No annual figure between 2021-08-31 and 2022-12-31. | |||
| 2021-08-31 | $20.99M | +105.1% | 2021-11-24, From 2020-09-01 |
| 2020-08-31 | $10.23M | -24.3% | 2021-11-24, From 2019-09-01 |
| 2019-08-31 | $13.52M | +12.9% | 2020-11-24, From 2018-09-01 |
| 2018-08-31 | $11.98M | +16.5% | 2019-11-27, From 2017-09-01 |
| 2017-08-31 | $10.28M | +33.4% | 2019-11-27, From 2016-09-01 |
| 2016-08-31 | $7.71M | +61.2% | 2018-11-28, From 2015-09-01 |
| 2015-08-31 | $4.78M | +45.9% | 2017-11-29, From 2014-09-01 |
| 2014-08-31 | $3.28M | n/c | 2016-11-25, From 2013-09-01 |
| 2013-08-31 | -$2.27M | n/c | 2015-11-25, From 2012-09-01 |
| 2012-08-31 | $1.68M | +45.0% | 2014-11-14, From 2011-09-01 |
| 2011-08-31 | $1.16M | n/a | 2012-12-12, From 2010-09-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Oramed Pharmaceuticals Inc. (ORMP) | 2025-12-31 | $6.38M | +0.9% |
| Immuneering Corp (IMRX) | 2025-12-31 | $42.05M | -12.3% |
| Design Therapeutics, Inc. (DSGN) | 2025-12-31 | $59.13M | +33.3% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $9.58M | +4.4% |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $109.16M | -35.5% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.26M | -3.7% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $138.09M | +868.4% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $26.81M | -22.0% |
Compare ORMP, IMRX, DSGN, EOLS side by side · Screen every company in Pharmaceutical Preparations ↗